CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities

Engineered T cell therapies such as chimeric antigen receptor (CAR) expressing T cells (CAR-T cells) have great potential to treat many human diseases; however, inflammatory toxicities associated with these therapies present safety risks and can greatly limit its widespread use. This article briefly...

Full description

Bibliographic Details
Main Authors:	Joseph W. Fischer, Nirjal Bhattarai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Series:	Frontiers in Immunology
Subjects:	CAR-T cells inflammation toxicities CRS neurotoxicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.693016/full

id	doaj-bd04eb2ce09347adb252d38afc6381e9
record_format	Article
spelling	doaj-bd04eb2ce09347adb252d38afc6381e92021-06-18T06:59:53ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.693016693016CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory ToxicitiesJoseph W. FischerNirjal BhattaraiEngineered T cell therapies such as chimeric antigen receptor (CAR) expressing T cells (CAR-T cells) have great potential to treat many human diseases; however, inflammatory toxicities associated with these therapies present safety risks and can greatly limit its widespread use. This article briefly reviews our current understanding of mechanisms for inflammatory toxicities during CAR T-cell therapy, current strategies for management and mitigation of these risks and highlights key areas of knowledge gap for future research.https://www.frontiersin.org/articles/10.3389/fimmu.2021.693016/fullCAR-T cellsinflammationtoxicitiesCRSneurotoxicity
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Joseph W. Fischer Nirjal Bhattarai
spellingShingle	Joseph W. Fischer Nirjal Bhattarai CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities Frontiers in Immunology CAR-T cells inflammation toxicities CRS neurotoxicity
author_facet	Joseph W. Fischer Nirjal Bhattarai
author_sort	Joseph W. Fischer
title	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
title_short	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
title_full	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
title_fullStr	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
title_full_unstemmed	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
title_sort	car-t cell therapy: mechanism, management, and mitigation of inflammatory toxicities
publisher	Frontiers Media S.A.
series	Frontiers in Immunology
issn	1664-3224
publishDate	2021-06-01
description	Engineered T cell therapies such as chimeric antigen receptor (CAR) expressing T cells (CAR-T cells) have great potential to treat many human diseases; however, inflammatory toxicities associated with these therapies present safety risks and can greatly limit its widespread use. This article briefly reviews our current understanding of mechanisms for inflammatory toxicities during CAR T-cell therapy, current strategies for management and mitigation of these risks and highlights key areas of knowledge gap for future research.
topic	CAR-T cells inflammation toxicities CRS neurotoxicity
url	https://www.frontiersin.org/articles/10.3389/fimmu.2021.693016/full
work_keys_str_mv	AT josephwfischer cartcelltherapymechanismmanagementandmitigationofinflammatorytoxicities AT nirjalbhattarai cartcelltherapymechanismmanagementandmitigationofinflammatorytoxicities
_version_	1721373397195161600

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities

Similar Items